This study is in progress, not accepting new patients
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Fate Therapeutics
- Links
- GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity
- ID
- NCT03319459
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated